Ascendis Pharma A/S (ASND) short interest & options flow
NASDAQAscendis Pharma reports Q3 results on September 4 with the Street firmly bullish but modestly dialling back expectations — while short interest has quietly built to its highest level in six weeks. The analyst picture has shifted slightly since the previous note. Oppenheimer's Leland Gershell moved in the opposite direction on Wednesday, raising his target to $312 from $304 while…
ASND short interest surges 20.8% in one week to 1.99M shares, driven by biotech sector volatility and competitive pressures in endocrinology therapeutics.
- Market cap
- $16.87B
- Next earnings
- 12 Nov 2026
Key data as of 8 Nov 2026
Latest signals on ASND
- Short Interest
ASND short interest surges 20.8% in one week to 1.99M shares, driven by biotech sector volatility and competitive pressures in endocrinology therapeutics.
ASND news and analysis
RSSNo long-form analysis yet for ASND. Pulse alerts and the live data picture are available on ORTEX.
Open ASND on ORTEX →Want the live picture for ASND?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ASND — free to start on ORTEX.
Sign up for free →Open ASND on ORTEX